Medical Developments International (MVP) Q3 2025 earnings summary

Executive summary

• Achieved strong quarterly operating performance with $1.7 million in operating cashflow for Q3 FY25, reversing a prior period outflow.

• Group revenue for Q3 FY25 reached $8.9 million, up $0.3 million year-over-year; YTD revenue at $28.9 million, up $5.2 million.

• Cash balance at 31 March 2025 stood at $19.1 million.

• Signed a new Penthrox distribution agreement with a French partner, Ethypharm.

Financial highlights

• Pain Management revenue for Q3 FY25 was $5.7 million, down $0.2 million year-over-year; YTD at $18.8 million, up $3.3 million.

• Respiratory revenue for Q3 FY25 was $3.2 million, up $0.5 million year-over-year; YTD at $10.1 million, up $1.9 million.

• Receipts from customers in Q3 FY25 were $10.6 million, $3.5 million higher than the prior year.

• Payments to suppliers and employees in Q3 FY25 were $9.0 million, down $2.1 million year-over-year.

• Cash generated from operating activities YTD was $0.9 million, an $11.3 million improvement year-over-year.

Outlook and guidance

• Earnings for H2 FY25 expected to be lower than H1 FY25 due to phasing and FX movements, but full-year underlying EBIT to be strongly improved on FY24.

• Positive operating cashflow anticipated for H2 FY25.

• Margin improvements of ~$3.5 million expected from pricing initiatives.